AzTrials
AzTrials

Surgical Approach & IncisionsAA+IVCNCT01608386

A Study of Anterior Approach Combined With Infrahepatic Inferior Vena Cava Clamping

A study testing IVC clamping in people with Surgical Approach & Incisions and Blood Loss, run by Eastern Hepatobiliary Surgery Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Anterior approach results in better operative and survival outcomes compared with the conventional approach in patients with large hepatocellular carcinoma (HCC), but anterior approach has the problem of bleeding from the hepatic vein. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Surgical Approach & Incisions, Blood Loss
What is being tested?
IVC clamping
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
No sites listed yet
Study dates
May 2012to Dec 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Understanding and being willing to sign the informed consent form
  • Aged 18-75 years
  • Diagnosed HCC by clinical findings and radiography,tumor size ≥ 5cm and located in the right lobe, need to perform right hemihepatectomy or major right hepatic resection (three Couinaud's segments)
  • Without any surgery contraindication
  • Child-Pugh grade A

Who cannot join

  • Refusal to take part in the study
  • With lymph node or extrahepatic metastases
  • History of previous hepatectomy or other abdominal operation
  • Those who can not be follow-up
  • Non-HCC

About this study

Official title: Anterior Approach Combined With Infrahepatic Inferior Vena Cava Clamping Right Hepatic Resection for Large Hepatocellular Carcinoma: A Prospective Randomized Controlled Study

Anterior approach results in better operative and survival outcomes compared with the conventional approach in patients with large hepatocellular carcinoma (HCC), but anterior approach has the problem of bleeding from the hepatic vein.

Our previous study showed that infrahepatic inferior vena cava (IVC) clamping can reduce blood loss during conventional hepatic resection. The investigators guess infrahepatic IVC clamping may also reduce blood loss in anterior approach right hepatic resection. So the investigators conduct this prospective, randomized, controlled trial to compare anterior approach combined with infrahepatic IVC clamping and anterior approach in major right hepatectomy for large HCC.

Read the detailed description

Traditionally, mobilisation of the right hemiliver followed by right hepatic vein control before parenchymal transection has been considered the standard approach to a major right hepatectomy. However, this approach is often difficult and hazardous when performing liver resection for large hepatocellular carcinoma (HCC) or for tumors with extrahepatic organ invasion in the right retrohepatic region.In setting of right hepatectomy by an anterior approach,liver mobilisation is performed only at the end of parenchymal transection, when all vascular connections have already been interrupted.The anterior approach was found to be associated with significantly less intraoperative blood loss, less blood transfusions and a lower hospital mortality rate.However,excessive bleeding can occur at the deeper plane of parenchymal transection from the right hepatic vein or middle hepatic vein.

Bleeding from the hepatic veins is closely related to the CVP.Our previous retrospective analysisfound that the infrahepatic inferior vena cava (IVC) clamping is efficacious in reducing CVP without the need of systemic fluid restriction and is associated with significantly less intraoperative blood loss during complex hepatectomy.

The aim of the present study was therefore to evaluate if the application of the anterior approach combined with infrahepatic IVC clamping during right hepatectomy for large HCC reduces intraoperative blood loss.

Being tested
IVC clamping
Keywords
Anterior approach, infrahepatic inferior vena cava clamping, hepatic resection
Medical subject headings
Surgical Wound, Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IVC clampingProcedure or surgery

    in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.

Study groups in NCT01608386
Study groupRoleWhat they receive
anterior approach+IVC clampingExperimentalUse anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
Receives: Procedure: IVC clamping
anterior approachNo interventionOnly use anterior approach in right hepatectomy for HCC patients.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. intraoperative total blood loss

    Measured: participants will be followed for the duration of the entire operation,an expected average of 140 minutes

Secondary outcomes (7)
  1. operation time

    Measured: the duration of the entire operation,an expected average of 140 minutes

  2. intraoperative CVP value

    Measured: participants will be followed for the duration of the parenchymal transection,an expected average of 20 minutes

  3. morbidity and mortality

    Measured: participants will be followed for the duration of the postoperative hospital stay,an expected average of 15 days

  4. postoperative hepatorenal function

    Measured: postoperative day 1,3 and 7

  5. postoperative hospital stay

    Measured: the duration of the postoperative hospital stay,an expected average of 15 days

  6. disease-free survival duration and overall survival duration

    Measured: the duration from operation to recurrence or death,an expected average of 3 years

  7. blood loss during parenchymal transection

    Measured: the duration of the parenchymal transection,an expected average of 20 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 May 2012 (estimated)
  2. Study startMay 2012
  3. Primary completionDec 2015 (estimated)
  4. Study completionDec 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01608386
Sponsor's protocol ID
EHBHKY2012-002-16
Acronym
AA+IVC
Status last verified
Aug 2015
First submitted
22 May 2012
Last updated
6 Aug 2015
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing IVC clamping in people with Surgical Approach & Incisions and Blood Loss, run by Eastern Hepatobiliary Surgery Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

intraoperative total blood loss (time frame: participants will be followed for the duration of the entire operation,an expected average of 140 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in